An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Area of Science:

• Hepatology
• Virology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infection affects over 170 million globally, causing chronic liver disease.
• Current interferon therapies are ineffective for HCV genotype 1 and poorly tolerated.
• The HCV NS3 protease is crucial for viral replication, making it a key therapeutic target.

Purpose of the Study:

• To identify and evaluate novel Hepatitis C virus NS3 protease inhibitors.
• To assess the efficacy and safety of BILN 2061, a new oral NS3 protease inhibitor, in human trials.

Main Methods:

• Identification of a class of specific and potent NS3 protease inhibitors.
• Clinical evaluation of BILN 2061 in patients with HCV genotype 1.

Main Results:

• BILN 2061 demonstrated significant reduction in HCV RNA plasma levels after 2 days of administration.
• Proof-of-concept was established for NS3 protease inhibitors in human subjects.
• BILN 2061 is orally bioavailable and represents the first-in-class NS3 protease inhibitor in human trials.

Conclusions:

• BILN 2061 shows promise as a novel therapeutic agent for Hepatitis C virus infection.
• Targeting viral enzymes like NS3 protease is a viable strategy for developing new HCV treatments.
• Further development of BILN 2061 could address the unmet need for effective and well-tolerated HCV therapies.